Open AccessLearning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations
Author(s) -
Fiorentino Michelangelo,
Giunchi Francesca,
Altimari Annalisa,
Di Tullio PierGiorgio,
Gruppioni Elisa,
Martorana Giuseppe,
Pinto Carmine
Publication year - 2014
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2013-0346
Subject(s) - gefitinib , medicine , urothelial carcinoma , cancer research , egfr inhibitors , renal pelvis , mutation , oncology , carcinoma , epidermal growth factor receptor , cancer , kidney , gene , genetics , bladder cancer , biology
This letter describes the first demonstration of clinical response to the anti‐EGFR inhibitor gefitinib in a case of urothelial carcinoma of the renal pelvis harboring a rare EGFR double mutation. New mutations and unexpected clinical responses should be always explored through wide‐spectrum mutational analyses.